Besides PI3K/Akt signalling, dysregulation of mitogen-activated protein kinase (MAPK) signalling, mediated by OPN, also shows a major role in cancer-acquired resistance to both targeted and chemotherapeutic drugs. This evidence concerns the gene SPP1 and cancer.